Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Onatasertib |
mTOR Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Onatasertib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
mTOR Inhibitor |
||||
Onvansertib |
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) | Solid Tumour | ||
|
Molecule
Onvansertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
||||
Oprozomib |
Proteasome Inhibitor | Hematologic (Multiple Myeloma) | ||
|
Molecule
Oprozomib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
||||
Orantinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Orantinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Orelabrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Orelabrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Pacritinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Pacritinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Pamiparib |
PARP Inhibitor | Solid Tumour | ||
|
Molecule
Pamiparib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
||||
Panitumumab |
Anti-EGFR mAb | Solid Tumour | ||
|
Molecule
Panitumumab
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
||||
Panobinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Panobinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Patidegib |
Hedgehog Pathway Inhibitor | Solid Tumour / Hematologic (AML) | ||
|
Molecule
Patidegib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
||||
Patritumab Deruxtecan |
ADC | Solid Tumour | ||
|
Molecule
Patritumab Deruxtecan
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Pazopanib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Pazopanib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
OnatasertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
mTOR Inhibitor |
|
OnvansertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
|
OprozomibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
|
OrantinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
OrelabrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
PacritinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
PamiparibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
|
PanitumumabTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-EGFR mAb |
|
PanobinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
PatidegibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour / Hematologic (AML)
Drug Class / Mechanism
Hedgehog Pathway Inhibitor |
|
Patritumab DeruxtecanTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
PazopanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|